logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
I

Ian E. Krop

memorial sloan kettering cancer center
H指数:99
被引数:4.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tucatinib–trastuzumab–capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results

Tucatinib-曲妥珠单抗-卡培他滨治疗HER2乳腺癌女性软脑膜转移: TBCRC049 2期研究结果

Nature Cancer
IF28.5
2026-03-180
OAAI
Rashmi K. Murthy; Barbara J. O’Brien; Donald A. Berry; Akshara Singareeka-Raghavendra; Maria Gule Monroe; Jason Johnson; Jason White; Jill Schwartz-Gomez; Ariel Topletz-Erickson; Mina Lobbous; Kristen Riley; Michelle Melisko; Aki Morikawa; Sherise D. Ferguson; John F. de Groot; Ian E. Krop; Vicente Valero; Mothaffar F. Rimawi; Antonio C. Wolff; Debu Tripathy; Nancy U. Lin; Erica M. Stringer-Reasor
Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial

疗效、安全性及预测性生物标志物：nab-paclitaxel联合pembrolizumab治疗激素受体阳性乳腺癌的随机试点试验

Nature Communications
IF15.7
2025-11-280
OAAI
Adrienne G. Waks; Jingxin Fu; Xiangying Chu; Busem Binboga Kurt; Tianyu Li; Thomas M. Kuntz; Yizhuo Shen; David Yang; Kevin Meli; Brendan Reardon; Jihye Park; Ann Partridge; Daniel Abravanel; Rinath Jeselsohn; Eileen Wrabel; Jillian Alberti; Molly DiLullo; Serenity Chen; Ayesha Mohammed-Abreu; Xiaopeng Sun; Justin M. Balko; Miranda Kleijn; William Audeh; Xochitl C. Morgan; Ian E. Krop; Nabihah Tayob; Eliezer M. Van Allen; Elizabeth A. Mittendorf; Sara M. Tolaney
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03

来自DESTINY-Breast01，DESTINY-Breast02和DESTINY-Breast03的HER2-positive转移性乳腺癌患者对曲妥珠单抗deruxtecan和相关生物标志物的最佳确认反应的汇总分析

Annals of Oncology
IF65.4
2025-11-180
PRE
C. Saura; J. Cortés; S. Modi; S.-B. Kim; E. Hamilton; S.A. Hurvitz; I.E. Krop; G. Curigliano; H. Iwata; S.-A. Im; P. Herbolsheimer; M. Karnoub; A. Boran; Y. Kuwahara; A. Egorov; F. André
Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030)

早期三阴性乳腺癌中视觉和计算评估的肿瘤浸润淋巴细胞预后价值（TBCRC-030）

JNCI-Journal of the National Cancer Institute
IF7.2
2025-11-010
PRE
Nader-Marta, Guilherme; Chu, Xiangying; Mukhopadhyay, Satabhisa; Abramson, Vandana G.; Brufsky, Adam; Stringer-Reasor, Erica Michelle; Dent, Susan Faye; Traina, Tiffany A.; Carey, Lisa A.; Rimawi, Mothaffar F.; Specht, Jennifer M.; Miller, Kathy D.; Santa-Maria, Cesar Augusto; Dasgupta, Tathagata; Kurt, Busem Binboga; Demeo, Michelle; Krop, Ian E.; Tung, Nadine M.; Schnitt, Stuart J.; Tayob, Nabihah; Mayer, Erica L.
Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA

检测细胞游离DNA中酪氨酸激酶抑制剂异质性耐药机制

Cell Genomics
IF9
2025-09-090
OAAI
Heather A. Parsons; Conor Messer; Katheryn Santos; Jakob Weiss; David Merrell; Brian P. Danysh; Melissa E. Hughes; Gregory J. Kirkner; Ashka Patel; Julian Hess; Kerry Sendrick; Chip Stewart; Elizabeth Grant; Kristy Schlueter-Kuck; Albert Grinshpun; Nikhil Wagle; Jamunarani Veeraraghavan; Jose Pablo Leone; Rachel A. Freedman; Otto Metzger; Rachel Schiff; Eric P. Winer; Sara M. Tolaney; Mothaffar Rimawi; Ian E. Krop; Gad Getz; Nancy U. Lin
Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients

预测年轻乳腺癌患者接受化疗和抗HER2治疗后卵巢功能丧失

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
IF7.2
2025-09-013
OAAI
Lambertini, Matteo; Allegranza, Deirdre; Laubender, Ruediger P.; Harbeck, Nadia; Swain, Sandra M.; Geyer, Charles E.; Slamon, Dennis J.; Bobba, Gabriella; Lambertini, Chiara; de Haas, Sanne; Restuccia, Eleonora; Vaz-Luis, Ines; Cameron, David A.; Krop, Ian E.; Winer, Eric P.; Anderson, Richard A.
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer

曲妥珠单抗德鲁替康后转移性乳腺癌患者的后续治疗方案结果

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
IF7.2
2025-09-012
PRE
Tarantino, Paolo; Lee, Do; Foldi, Julia; Soulos, Pamela R.; Gross, Cary P.; O'Meara, Tess; Grinda, Thomas; Morganti, Stefania; Waks, Adrienne G.; Winer, Eric P.; Lin, Nancy U.; Krop, Ian E.; Tolaney, Sara M.; Sammons, Sarah; Lustberg, Maryam
Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)

安全性概述及inavolisib单药和联合疗法在PIK3CA突变、HR阳性、HER2阴性晚期乳腺癌中的管理（GO39374）

ESMO Open
IF8.3
2025-07-010
PRE
V. Gambardella; M.K. Accordino; P.L. Bedard; A. Cervantes; E. Hamilton; A. Italiano; K. Kalinsky; I.E. Krop; M. Oliveira; C. Saura; P. Schmid; N.C. Turner; A. Varga; A. Fernandez-Saranillo; Y. Jin; S. Royer-Joo; U. Peters; N. Shankar; J.L. Schutzman; D. Juric; K.L. Jhaveri
Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer

曲妥珠单抗德鲁替康（trastuzumab deruxtecan）在不同生物标志物状态、治疗线数以及之前是否接受过沙西妥珠单抗戈维替康（sacituzumab govitecan）治疗的患者中的疗效，基于一项大型真实世界数据库的转移性乳腺癌患者研究。

ESMO Open
IF8.3
2025-07-010
PRE
P. Tarantino; D. Lee; J. Foldi; P.R. Soulos; C.P. Gross; T. Grinda; E.P. Winer; N.U. Lin; I.E. Krop; S.M. Tolaney; M. Lustberg; S. Sammons
A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
BREAST
IF7.9
2025-06-010
OAAI
Hennessy, Maeve A.; Cimino-Mathews, Ashley; Carter, Jodi M.; Kachergus, Jennifer M.; Ma, Yaohua; Leal, Jeffrey P.; Solnes, Lilja B.; Abramson, Vandana G.; Carey, Lisa A.; Rimawi, Mothaffar; Specht, Jennifer; Storniolo, Anna Maria; Vaklavas, Christos; Krop, Ian; Winer, Eric; Denbow, Rita; Valero, Vincente; Wolff, Antonio C.; Wahl, Richard L.; Huang, Chiung-Yu; Stearns, Vered; Thompson, E. Aubrey; Connolly, Roisin M.
A Randomized Phase 2 Study of Neratinib With or Without Fulvestrant for Patients With HER2-Positive, Estrogen Receptor-Positive Metastatic Breast Cancer

一项关于奈拉替尼联合或不联合氟维司群治疗HER2阳性、雌激素受体阳性转移性乳腺癌的随机II期研究

Clinical Breast Cancer
IF2.5
2025-05-160
PRE
Stefania Morganti; Xiangying Chu; Tarah J. Ballinger; Nisha Unni; Sarah Sinclair; Robert Wesolowski; Alyssa M. Pereslete; Paulina Lange; Nabihah Tayob; Nancy U. Lin; Jose P. Leone; Ian E. Krop; Sara M. Tolaney; Heather A. Parsons
Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium

乳腺癌管理中的争议与关键知识空白专家观点：第一届弥合乳腺癌知识空白研讨会的会议录

Clinical Breast Cancer
IF2.5
2025-04-080
PRE
Komal Jhaveri; Carey K. Anders; Aditya Bardia; Manali Bhave; A. Jo Chien; Ian Krop; Tiffany A. Traina; Yara Abdou; Reva Basho; Alison K. Conlin; Francisco J. Esteva; Kevin R. Fox; Vijayakrishna Gadi; Peter A. Kaufman; Anya Litvak; Cynthia X. Ma; Eleftherios P. Mamounas; Heather McArthur; Kelly McCann; Zahi Mitri; Rebecca Shatsky; Melinda Telli; Mylin A. Torres; Kevin Kalinsky
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases

人表皮生长因子受体2 (HER2) 阳性转移性乳腺癌脑转移患者曲妥珠单抗deruxtecan的汇总分析

ANNALS OF ONCOLOGY
IF65.4
2024-12-012
OAAI
Andre, F.; Cortes, J.; Curigliano, G.; Modi, S.; Li, W.; Park, Y. H.; Chung, W. -p.; Kim, S. -b.; Yamashita, T.; Pedrini, J. L.; Im, S. -a.; Tseng, L. -m.; Harbeck, N.; Krop, I.; Nakatani, S.; Tecson, K.; Ashfaque, S.; Egorov, A.; Hurvitz, S. A.
Event-free Survival by Residual Cancer Burden (RCB) and Intratumor HER2 Heterogeneity after Neoadjuvant T-DM1 and Pertuzumab for Early-stage HER2-positive Breast Cancer
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Metzger, Otto; Kim, Se Eun; Tayob, Nabihah; Viale, Giuseppe; Yardley, Denise; Prat, Aleix; Abramson, Vandana; Spring, Laura; Waks, Adrienne; Wrabel, Eileen; Demeo, Michelle; Bardia, Aditya; Dell'Orto, Patrizia; Russo, Leila; King, Tari; Michor, Franziska; Winer, Eric; Polyak, Kornelia; Tolaney, Sara; Krop, Ian
AVIATOR/ TBCRC045: A randomized phase II study of vinorelbine (N) plus trastuzumab (H) alone or combined with avelumab (A) plus /- utomilumab (U) in patients (pts) with HER2+metastatic breast cancer (MBC) (NCT03414658)
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Waks, Adrienne; Shi, Ruichao; Regan, Meredith; Dang, Chau; Santa-Maria, Cesar; Westbrook, Kelly; Abramson, Vandana; Murthy, Rashmi; Nanda, Rita; Rugo, Hope; Clark, Amy; Mainor, Candace; Dees, Claire; Hoyos, Valentina; Miller, Kathy; Stringer-Reasor, Erica; Hunter, Natasha; Oh, Sun Young; Demeo, Michelle; Okpoebo, Amanda; Elias, Erin; Kurt, Busem; Lin, Nancy; Rimawi, Mothaffar; Wolff, Antonio; Mittendorf, Elizabeth; Goel, Shom; Tolaney, Sara; Loi, Sherene; Krop, Ian
Anti-Mullerian hormone in Young women with breast CAncer to predict permanent loss of ovarian function after chemotherapy and anti-HER2 therapy (AMYCA): a biomarker analysis of the BETH and KAITLIN trials
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Lambertini, Matteo; Allegranza, Deirdre; Laubender, Ruediger; Harbeck, Nadia; Swain, Sandra; Geyer, Charles; Slamon, Dennis; Bobba, Gabriella; Lambertini, Chiara; De Haas, Sanne Lysbet; Restuccia, Eleonora; Luis, Ines Vaz; Cameron, David; Krop, Ian; Winer, Eric; Anderson, Richard

研究方向

暂未获取到该数据
E
Eric P. Winer
H 指数:170论文数:1,624被引数:12.8万
S
Sara M. Tolaney
H 指数:83论文数:1,340被引数:3.5万
N
Nancy U. Lin
H 指数:95论文数:1,073被引数:4.1万
A
Antonio C. Wolff
H 指数:99论文数:905被引数:5.8万
L
Lisa A. Carey
H 指数:104论文数:988被引数:5.3万
M
Mothaffar F. Rimawi
H 指数:52论文数:509被引数:1.0万
D
Denise A. Yardley
H 指数:67论文数:560被引数:2.6万
N
Nabihah Tayob
H 指数:35论文数:453被引数:5,341
A
Ann H. Partridge
H 指数:100论文数:1,042被引数:4.5万
A
Adrienne G. Waks
H 指数:22论文数:215被引数:8,422